You are about to leave DOPTELETHCP.com and go to an external page.
Please note that Sobi is not responsible for the content of the website you are about to visit.
CONTINUEGo back
For US healthcare professionals only
- Important Safety Information
- Prescribing Information
- Patient Information Leaflet
- For Patients
For US healthcare professionals only
Hear from
Expert Speakers
Below you’ll find a series of clinical presentations from your peers on all things ITP and Doptelet. Watch as Drs. Hillary Maitland and Steven Fein help you discover Doptelet and share how to implement it in your practice.
Convenient Oral Dosing With Doptelet® (avatrombopag)
Dr. Hillary Maitland shares how Doptelet offers administration convenience.
Watch Now
Dr. Hillary Maitland shares how Doptelet offers administration convenience.
Watch Now
Featured speaker: Dr. Hillary Maitland
Raising & Maintaining Platelet Counts in Chronic Immune Thrombocytopenia (ITP)
Dr. Hillary Maitland shares clinical trial data for Doptelet.
Recommended Dosing and Titration for Doptelet® (avatrombopag)
Dr. Hillary Maitland shares dosing recommendations for Doptelet.
Featured speaker: Dr. Steven Fein
Raising & Maintaining Platelet Counts in Chronic Immune Thrombocytopenia (ITP)
Dr. Steven Fein shares clinical trial data for Doptelet.
Convenient Oral Dosing With Doptelet® (avatrombopag)
Dr. Steven Fein shares how Doptelet offers administration convenience.
Recommended Dosing and Titration for Doptelet® (avatrombopag)
Dr. Steven Fein shares dosing recommendations for Doptelet.
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.
Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.
DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.
Serious Adverse Reactions
Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).
Adverse Reactions
The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.
Postmarketing Experience
Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.
These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com
To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.
For WAC pricing, visit doptelethcp.com/wac-pricing.
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
